Although this excludes the dystrophinopathy-associated change in liver FABP5 as a robust and highly specific biomarker of X-linked muscular dystrophy, altered FABP5 levels may nevertheless be useful as a general pathophysiological marker in conjunction with other disease indicators. This evidence concerns the gene FABP5 and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.